Skip to content
MS
PW-040 Lipid Metabolism Catabolic (cholesterol disposal) unreviewed

Bile Acid Synthesis

Cholesterol Conjugated bile salts (glyco-/tauro-cholate and chenodeoxycholate)
Compartment
ER + mitochondrion + peroxisome
Main tissue
Liver
Rate-limiting
Cholesterol 7-alpha-hydroxylase (CYP7A1)
Steps
4

Reaction steps

In source order, 4 total

showing 1–4
  1. 1

    Cholesterol + O2 + NADPH -> 7-alpha-hydroxycholesterol

    Notes

    Rate-limiting and committed step of the classic (neutral) pathway; feedback-inhibited by bile acids returning via FXR/FGF19, and induced when bile acids are sequestered by resins.

  2. 2

    7-alpha-hydroxycholesterol -> cholic acid or chenodeoxycholic acid

    Notes

    CYP8B1 activity determines the ratio of cholic to chenodeoxycholic acid (the primary bile acids).

  3. 3

    Bile acid + glycine or taurine -> glyco- or tauro-conjugated bile salt

    Notes

    Conjugation lowers the pKa so the bile salts stay ionised and act as detergents at intestinal pH.

  4. 4

    Primary bile salts -> deoxycholate and lithocholate (gut bacteria) -> enterohepatic recycling

    Notes

    About 95% of bile salts are reabsorbed in the terminal ileum by ASBT and returned to liver; loss of ileum or resin binding forces cholesterol into new bile acid synthesis.

Showing all 4 steps.

Recent literature

Live Europe PMC search

Europe PMC · from cache · sorted by publication date

  1. 1
  2. 2
    Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.

    Liu J, Zhao P, Jiang D, Li S, Jin C, Xu D, Wang X, Chen Y, Tang B, Qu X. · 2026-05-29

    open access unreviewed
  3. 3
    A novel bile salt hydrolase-producing <i>Ligilactobacillus salivarius</i> prevents diet-induced obesity via regulation of bile acid metabolism and glucagon-like peptide 1 restoration.

    Lv J, Zhou L, Dai X, Landberg R, Meng H, Tian H, Zhang S, Liu T, Yin X, Zhang J, Song X, Bonny C, Blum S, Cao… · 2026-05-06

    open access unreviewed
  4. 4
  5. 5
    Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.

    Yang W, Hao C, Wang N, Xie J, Zhou B, Yang Z, Zheng A, Wei J, Li C, Xie C, Li H, Lei G, Zeng C. · 2026-04-22

    open access unreviewed
  6. 6
    Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.

    Morineau N, Tessoulin B, Guimard T, Papin M, Roquilly A, Le Gouill S, Montassier E. · 2026-04-19

    open access unreviewed
  7. 7
    Re-establishing bile acid composition after treatment of recurrent <i>Clostridioides difficile</i> infection with fecal microbiota transplantation compared with oral vancomycin or a 12-strain bacterial mixture.

    Rode AA, Duboc H, Lamazière A, Rainteau D, Humbert L, Gauliard E, Chehri M, Petersen AM, Helms M, Schønning K… · 2026-04-17

    open access unreviewed
  8. 8
    A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.

    Biagioli M, Di Giorgio C, Marchianò S, Sensini B, Urbani G, Giannelli E, Lachi G, Massa C, Sette MR, Paniconi… · 2026-03-18

    cited 1× open access unreviewed
  9. 9
    Growth factor applications and clinical translation: advances and challenges.

    Tu Y, Li B, Zheng S, Qu G, Li M, Li S, Shao C. · 2026-03-16

    cited 1× open access unreviewed
  10. 10
    Multi-target protective effects of <i>Agrimonia pilosa</i> Ledeb. against metabolic dysfunction-associated steatohepatitis in mice.

    Fu X, You J, Yang Y, Qi S, Yang S, Qu X, Shao Y, Wang N, Wang Z, Li Y, Zheng M, Yang H, Zhao J, He X, He Y. · 2026-03-09

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.